IHE
iShares U.S. Pharmaceuticals ETF·Financial Services
87.15
1.235%(−1.09)
Market ClosedLast Updated: — ET
52W L: $61.6452W H: $92.30
IHE NEWS
zacks.com
Mar 9
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund launched on May 1, 2006.
seekingalpha.com
Feb 27
IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features
The iShares U.S. Pharmaceuticals ETF is led by Johnson & Johnson and Eli Lilly, two stocks whose earnings per share has nearly doubled over the last twelve months. Also in IHE's top ten holdings list are lower-growth but cheaper stocks like Pfizer. Overall, this balance results in a portfolio with very appealing growth-at-a-reasonable-price statistics. My calculations show that IHE's one-year estimated EPS growth rate is an exceptional 19.07%, while its forward P/E ratio sits at just 15.69x.
zacks.com
Jan 27
3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers
Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
